INSULCLOCK · Project

Smart Clip-On Device That Tracks Insulin Pen Doses and Alerts Caregivers Automatically

healthPilotedTRL 7

Imagine you use an insulin pen every day but sometimes forget whether you already took your dose, or you accidentally inject the wrong amount. INSULCLOCK is a small clip-on gadget that attaches to any standard insulin pen and automatically records every injection — how much, when, and at what temperature. It sends that data to your phone and to the cloud, so your doctor or family can check in without you having to write anything down. Think of it like a fitness tracker, but for insulin management.

By the numbers

380 million

Expected global diabetes patient pool by 2025

8 billion €

Insulin pen market size in 2013

Compound annual growth rate of insulin pen market

25%

Share of diabetics dependent on daily insulin injections

2/3

Share of insulin volume injected via pens

1.48M€

Phase 2 project budget

The business problem

What needed solving

Millions of insulin-dependent diabetics struggle with tracking their daily injections — missing doses, double-dosing, or storing insulin at wrong temperatures. Treatment failure leads to serious vascular and nerve complications. Caregivers and doctors have no reliable way to monitor adherence remotely, leaving patients unsupported between appointments.

The solution

What was built

INSULCLOCK built a universal, reusable clip-on smart device for insulin pens that automatically records injection data (dose, time, temperature) and syncs it to the cloud via a mobile app. The project delivered industrial prototypes ready for trials and demonstrations, plus 8 additional deliverables covering the full product development cycle.

Audience

Who needs this

Health insurance companies seeking to reduce diabetes complication costs through adherence monitoringPharmaceutical companies manufacturing insulin pens wanting to add connected-device capabilitiesDigital health and telehealth platforms needing hardware for remote chronic disease managementHospital pharmacy departments managing insulin-dependent outpatientsHome care agencies supporting elderly diabetic patients

Business applications

Who can put this to work

Health Insurance

enterprise

Target: Health insurance companies looking to reduce diabetes complication costs

If you are a health insurance provider dealing with high costs from diabetes complications — this project developed a universal clip-on device for insulin pens that automatically tracks dosage compliance. With 25% of diabetics depending on daily insulin injections and treatment failure leading to costly vascular and nerve complications, real-time adherence monitoring could help you identify at-risk patients early and reduce long-term claims.

Pharmaceutical

enterprise

Target: Pharmaceutical companies manufacturing insulin or insulin pens

If you are a pharma company selling insulin pens into a market that totaled above 8 billion € in 2013 with 9% CAGR — this project built a universal, reusable smart attachment that turns any standard pen into a connected device. Adding INSULCLOCK compatibility to your product line creates a digital health ecosystem around your existing hardware, generating new data-driven revenue streams and patient loyalty.

Digital Health / Home Care

any

Target: Home care and telehealth platform providers

If you are a digital health platform serving chronic disease patients — this project developed a cloud-connected insulin tracking device that shares real-time data with caregivers. With an expected global pool of 380 million diabetes patients by 2025 and 2/3 of insulin volume delivered via pens, integrating this device into your remote monitoring platform gives you a ready-made hardware solution for insulin adherence tracking.

Frequently asked

Quick answers

What would it cost to license or integrate this technology?

The project does not disclose per-unit pricing or licensing terms. The product was developed by a single Spanish SME (INSULCLOUD) through EU SME Instrument Phase 2 funding. Interested companies should contact the coordinator directly to discuss commercial terms.

Can this work at industrial scale across different insulin pen brands?

Yes — universality is a core design feature. INSULCLOCK was designed to be compatible with standard insulin pens regardless of manufacturer, and the project specifically produced industrial prototypes for trials and demonstrators. The device is also described as reusable, reducing per-patient deployment cost at scale.

What is the IP situation — can we license this?

The IP is held by INSULCLOUD, the sole consortium partner and a Spanish SME. Since this was a single-company SME Instrument project with no university or research institute partners, IP ownership is straightforward. Licensing or distribution partnerships would be negotiated directly with the company.

Is this compliant with medical device regulations?

The project objective mentions security, assistance, and privacy as design priorities for cloud data storage. However, specific regulatory certifications (CE marking, MDR compliance) are not detailed in available project data. Prospective partners should verify current regulatory status with the manufacturer.

How long until this could be deployed in our product line?

The project ran for 15 months (Phase 2) and completed industrial prototypes. The company website (insulclock.com) remains active, suggesting the product has progressed beyond the EU project phase. Based on available project data, integration timelines would depend on the specific partnership model.

Can this integrate with existing hospital or pharmacy IT systems?

INSULCLOCK uses cloud storage and mobile technologies to record and share insulin data. The project emphasizes data security and privacy. Based on available project data, the platform architecture supports caregiver access, which suggests API or data-sharing capabilities, but specific EHR integration details are not documented.

Consortium

Who built it

This is a solo-company project: INSULCLOUD, a Spanish SME, is the only consortium partner. That is typical for SME Instrument Phase 2 grants, which are designed to help individual companies bring near-market innovations to commercial scale. The 100% industry composition means there are no academic partners — all IP sits with one company, making licensing negotiations straightforward. The lack of clinical or university partners may mean the company sought external validation separately. With 9 total deliverables including industrial prototypes, the project was execution-focused rather than research-heavy.

INSULCLOUDCoordinator · ES

How to reach the team

INSULCLOUD is a Spanish SME — contact via their website insulclock.com or through SciTransfer for a facilitated introduction

Order a report on this consortium See INSULCLOUD profile →

Next steps

Talk to the team behind this work.

Want to explore integrating insulin adherence tracking into your product line or patient programs? SciTransfer can connect you directly with the INSULCLOCK team and provide a detailed technology brief.

Order a report on this topic More in Health & Biomedical